Literature DB >> 33770730

Oridonin ameliorates noise-induced hearing loss by blocking NLRP3 - NEK7 mediated inflammasome activation.

Menghua Li1, Yan Zhang2, Shiwei Qiu3, Wei Zhuang4, Wen Jiang4, Caiji Wang4, Shili Zhang4, Zijun Zhou4, Tiantian Sun4, Zhaoyang Ke5, Weiwei Guo6, Yuehua Qiao7, Xi Shi8.   

Abstract

Inflammation is involved in noise-induced hearing loss (NIHL), but the mechanism is still unknown. The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, which triggers the inflammatory cascade, has been implicated in several inflammatory diseases in response to oxidative stress. However, whether the NLRP3 inflammasome is a key factor for permanent NIHL is still unknown. In this study, quantitative real-time polymerase chain reaction (qPCR), western blot, and enzyme-linked immunosorbent assays (ELISAs) demonstrated that the expression levels of activated caspase-1, interleukin (IL)-1β, IL-18, and NLRP3 were significantly increased in the cochleae of mice exposed to broadband noise (120 dB) for 4 h, compared with the control group. These results indicate that the activation of inflammasomes in the cochleae of mice during the pathological process of NIHL as well as NLRP3, a sensor protein of reactive oxygen species (ROS), may be key factors for inflammasome assembly and subsequent inflammation in cochleae. Moreover, many recent studies have revealed that NEK7 is an important component and regulator of NLRP3 inflammasomes by interacting with NLRP3 directly and that these interactions can be interrupted by oridonin. Here, we further determined that treatment with oridonin could indeed interrupt the interaction between NLRP3 and NEK7 as well as inhibit the downstream inflammasome activation in mouse cochleae after noise exposure. Furthermore, we tested anakinra, another inflammatory inhibitor, and it was shown to partially alleviate the degree of hearing impairment in some frequencies in an NIHL mouse model. These discoveries suggest that inhibiting NLRP3 inflammasomes and the downstream signaling pathway may provide a new strategy for the clinical treatment of NIHL.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammasomes; NEK7; NIHL; NLRP3; Oridonin

Mesh:

Substances:

Year:  2021        PMID: 33770730     DOI: 10.1016/j.intimp.2021.107576

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  2 in total

Review 1.  NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases.

Authors:  Jin Wang; Simeng Chen; Min Liu; Min Zhang; Xiaoyi Jia
Journal:  Inflammopharmacology       Date:  2022-07-13       Impact factor: 5.093

2.  IL-1R/C3aR signaling regulates synaptic pruning in the prefrontal cortex of depression.

Authors:  Man-Man Zhang; Min-Xia Guo; Qiu-Ping Zhang; Xue-Qin Chen; Na-Zhi Li; Qing Liu; Jie Cheng; Shi-Le Wang; Guang-Hui Xu; Cheng-Fu Li; Ji-Xiao Zhu; Li-Tao Yi
Journal:  Cell Biosci       Date:  2022-06-17       Impact factor: 9.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.